|
|
Vaccine Detail
|
Bivalent Vaccine with Adjuvant OPT-821 |
| Vaccine Information |
- Vaccine Name: Bivalent Vaccine with Adjuvant OPT-821
- Target Pathogen: Cancer
- Target Disease: Cancer
- Type: Conjugate vaccine
- Status: Clinical trial
- Host Species for Licensed Use: None
- Antigen: GD2L and GD3L (NCT00911560)
- Immunization Route: subcutaneous injection
- Description: This is a bivalent vaccine with the antigens GD2L and GD3L for patients with High-Risk Neuroblastoma. The antigens are linked to KLH and mixed with OPT-821. It is given in combination with oral β-glucan, which can help white blood cells kill cancer. Ref6029:NCT00911560]
|
| Host Response |
|
|
| References |
NCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma [https://clinicaltrials.gov/study/NCT00911560]
|
|
